Simcere Pharmaceutical Group Limited (HKG: 2096)

Simcere Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,755	2,007	1,658	973.14	3,270	354.8
Short-Term Investments	301.43	11.14	964.23	1,210	-	543.94
Trading Asset Securities	-	-	-	-	3.63	3.06
Cash & Short-Term Investments	3,056	2,018	2,623	2,183	3,274	901.8
Cash Growth	24.38%	-23.04%	20.12%	-33.31%	263.04%	-37.85%
Accounts Receivable	2,417	2,645	2,339	2,399	1,871	1,337
Other Receivables	91.13	50.73	39.89	37.37	43.79	26.5
Receivables	2,508	2,695	2,379	2,436	1,915	1,363
Inventory	754.02	770.14	371.59	290.96	311.13	300.39
Other Current Assets	99.46	155.13	85.61	69.24	967.03	332.04
Total Current Assets	6,418	5,639	5,458	4,980	6,467	2,898
Property, Plant & Equipment	2,247	2,170	2,139	1,931	2,128	1,870
Long-Term Investments	1,436	1,580	2,258	2,651	1,825	1,484
Goodwill	142.47	142.47	172.79	172.79	172.79	142.47
Other Intangible Assets	953.5	715.79	379.9	59.69	77.11	33.77
Long-Term Deferred Tax Assets	396.78	317	326.71	289.97	210.09	274.7
Other Long-Term Assets	19.72	188.95	53.79	76.56	63.53	64.74
Total Assets	11,713	10,854	10,789	10,161	10,943	6,767
Accounts Payable	355.91	317.22	335.43	323.95	242.08	254.85
Accrued Expenses	895.02	1,045	1,124	1,032	1,155	1,118
Short-Term Debt	993.77	762.43	1,184	991.57	1,561	1,509
Current Portion of Long-Term Debt	0.71	252.71	108.37	538.51	232.2	135.21
Current Portion of Leases	83.83	79.85	58.76	31.56	38.1	26.21
Current Income Taxes Payable	127.08	17.9	10.56	16.16	-	85.53
Current Unearned Revenue	38.98	43.31	63.34	26.14	18.76	16.68
Other Current Liabilities	561.74	167	82.41	103.7	249.91	283.64
Total Current Liabilities	3,057	2,686	2,967	3,064	3,497	3,429
Long-Term Debt	8.51	205.85	-	-	1,276	1,139
Long-Term Leases	95.05	128.4	155.92	74.24	193.43	131.6
Long-Term Unearned Revenue	438.71	393.11	403.35	417.61	447.95	470.53
Long-Term Deferred Tax Liabilities	65.03	102.68	115.29	142.77	193.6	116.6
Other Long-Term Liabilities	1,140	115	-	-	-	-
Total Liabilities	4,804	3,631	3,641	3,698	5,608	5,286
Common Stock	3,174	3,174	3,081	3,003	3,003	0.21
Retained Earnings	3,491	3,837	3,831	3,294	2,147	1,466
Comprehensive Income & Other	244.21	211.61	219.72	139.96	151.48	14.53
Total Common Equity	6,909	7,223	7,132	6,437	5,302	1,480
Minority Interest	-	-	16.06	25.76	33.94	-
Shareholders' Equity	6,909	7,223	7,148	6,463	5,336	1,480
Total Liabilities & Equity	11,713	10,854	10,789	10,161	10,943	6,767
Total Debt	1,182	1,429	1,507	1,636	3,300	2,941
Net Cash (Debt)	1,875	589.08	1,116	547.34	-26.14	-2,039
Net Cash Growth	44.10%	-47.21%	103.86%	-	-	-
Net Cash Per Share	0.73	0.23	0.43	0.21	-0.01	-0.87
Filing Date Shares Outstanding	2,537	2,617	2,660	2,628	2,609	2,345
Total Common Shares Outstanding	2,537	2,617	2,660	2,628	2,609	2,345
Working Capital	3,361	2,953	2,492	1,916	2,970	-530.86
Book Value Per Share	2.72	2.76	2.68	2.45	2.03	0.63
Tangible Book Value	5,813	6,364	6,579	6,205	5,052	1,304
Tangible Book Value Per Share	2.29	2.43	2.47	2.36	1.94	0.56
Machinery	-	2,632	2,811	2,528	2,572	1,943
Construction In Progress	-	343.47	202.13	95.75	66.43	281.83

Source: S&P Capital IQ. Standard template. Financial Sources.